Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Biotech startup developing nucleic acid drugs using circular RNA technology for RNA therapeutics, offering longer expression.
Circular Code Biology is a biotechnology company based in an undisclosed location that develops nucleic acid drugs utilizing circular RNA technology to achieve longer expression duration and lower immunogenicity than traditional RNA therapeutics. The enterprise focuses on advancing circular RNA for therapeutic applications, building upon initial scientific discoveries regarding the coding function of these specific molecules. To support its clinical pipeline and ongoing drug discovery efforts, the startup recently secured a multi-million-dollar Series A financing round from venture capital investors. The executive leadership brings academic and research experience from prominent global institutions, specifically including Tsinghua University and Yale University. Within its first two years of operation, the firm achieved significant advancements in key circular RNA drug development technologies and initiated early-stage human clinical programs. Circular Code Biology was founded in 2021 by Chenxiang Tang alongside two scientific co-founders.
Circular Code Biology has raised $20.0M across 1 funding round.
Circular Code Biology has raised $20.0M in total across 1 funding round.
Circular Code Biology has raised $20.0M in total across 1 funding round.
Circular Code Biology's investors include K2 Venture Partners, Efung Capital, Kaitai Capital.
Circular Code Biology has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Pre-Series A in June 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 9, 2022 | $20M Seed Plus | K2 Venture Partners | Efung Capital, Kaitai Capital | Announced |